Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Crizotinib
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of MesenchymalâEpithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
